Utilizing AI to Save Lives and Cut Costs
Millions of people are on track to experience a heart attack, heart failure, stroke, lung cancer, COPD, aortic dissection, osteoporosis and fatty liver disease that can be detected with a chest CT scan powered by HeartLung's AI.
Unfortunately, most are unaware of their high risk and will find out too late.
Are you among them?
AI CVD
TM
AI-CVD™ is an AI-powered cardiovascular disease detection technology that analyzes CT scans to identify hidden heart risks, enabling early intervention and personalized prevention strategies.
* Pending FDA Clearance for Patient Care.
* Available Only for Research Studies.
* Two AI-CVD™ components, AutoBMD™ and AutoChamber™ are FDA-cleared. The remaining components are pending approval.
* Click on the individual modules above to learn more
Detects What Humans Miss
AutoBMD™ is the first FDA-Approved, AI-Powered, Cloud-Based, Opportunistic Bone Mineral Density (BMD) Measurement Test that works on any CT scan.
It enables your doctor to take advantage of CT scans ordered for other purposes and measure your bone density.
don't know about their severe bone loss and hidden spinal fractures while suffering from body pain.
don't know about their severe bone loss and hidden spinal fractures while suffering from body pain.
AutoChamber™ Receives FDA Breakthrough Designation and Marketing Authorization
Introducing
AutoChamber
TM
Breakthrough Designation
AutoChamber™ is the first FDA-approved AI that received “Breakthrough” designation for enabling physicians to detect patients with enlarged cardiac chambers and left ventricular hypertrophy that are invisible to the human eye.
Every year, over 10 million chest CT scans are done in the US alone and among them many asymptomatic patients with enlarged heart chambers are missed resulting in late-stage heart failure, atrial fibrillation, stroke, and sudden cardiac death. AutoChamber™ AI can help physicians fill this gap and save many lives from preventable cardiovascular death.
1st Annual Conference on Integrating Early Detection of Heart and Lung Disease through Low-Dose CT
HeartLung participated in the world's first conference on integrating early detection of heart and lung disease through low-dose CT, featuring global leaders in preventive cardiology and lung cancer screening.
HeartLung is a proud sponsor of the conference.
Conference Highlight
AI-CVD: Opportunistic Detection of CVD Biomarkers
Did you know...
nearly 43 million Americans don't know about their bone loss
or hidden spinal fracture while suffering from body pain?
.png)
